NEOS Investment Management LLC Buys 9,099 Shares of Zoetis Inc. $ZTS

NEOS Investment Management LLC increased its stake in shares of Zoetis Inc. (NYSE:ZTS) by 14.5% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 71,746 shares of the company’s stock after acquiring an additional 9,099 shares during the period. NEOS Investment Management LLC’s holdings in Zoetis were worth $5,156,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Brighton Jones LLC boosted its position in shares of Zoetis by 180.4% during the fourth quarter. Brighton Jones LLC now owns 4,629 shares of the company’s stock worth $754,000 after buying an additional 2,978 shares during the period. Empowered Funds LLC lifted its stake in Zoetis by 6.2% in the 1st quarter. Empowered Funds LLC now owns 11,293 shares of the company’s stock valued at $1,859,000 after acquiring an additional 657 shares in the last quarter. Intech Investment Management LLC lifted its stake in Zoetis by 17.2% in the 1st quarter. Intech Investment Management LLC now owns 8,347 shares of the company’s stock valued at $1,374,000 after acquiring an additional 1,224 shares in the last quarter. Sivia Capital Partners LLC boosted its position in Zoetis by 73.8% during the 2nd quarter. Sivia Capital Partners LLC now owns 3,348 shares of the company’s stock worth $522,000 after acquiring an additional 1,422 shares during the last quarter. Finally, Glenview Trust co boosted its position in Zoetis by 11.8% during the 2nd quarter. Glenview Trust co now owns 4,780 shares of the company’s stock worth $745,000 after acquiring an additional 506 shares during the last quarter. 92.80% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on ZTS shares. Weiss Ratings downgraded shares of Zoetis from a “sell (d+)” rating to a “sell (d)” rating in a report on Friday, June 12th. BNP Paribas Exane reduced their target price on shares of Zoetis from $146.00 to $110.00 and set an “outperform” rating for the company in a report on Tuesday, August 11th. Cantor Fitzgerald set a $94.00 target price on shares of Zoetis in a research report on Tuesday, August 25th. UBS Group lowered their price target on shares of Zoetis from $85.00 to $80.00 and set a “neutral” rating on the stock in a research note on Friday, August 7th. Finally, Piper Sandler cut their price target on shares of Zoetis from $90.00 to $80.00 and set a “neutral” rating on the stock in a research report on Monday, August 10th. Eight equities research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $107.43.

Zoetis Price Performance

NYSE:ZTS opened at $75.70 on Monday. Zoetis Inc. has a 1-year low of $71.00 and a 1-year high of $155.15. The company has a current ratio of 3.08, a quick ratio of 1.84 and a debt-to-equity ratio of 2.87. The firm has a fifty day simple moving average of $75.53 and a 200 day simple moving average of $93.61. The stock has a market capitalization of $31.28 billion, a PE ratio of 12.47, a P/E/G ratio of 1.77 and a beta of 0.73.

Zoetis (NYSE:ZTS) last issued its earnings results on Thursday, August 6th. The company reported $1.87 earnings per share for the quarter, topping analysts’ consensus estimates of $1.85 by $0.02. The business had revenue of $2.47 billion for the quarter, compared to the consensus estimate of $2.50 billion. Zoetis had a net margin of 27.49% and a return on equity of 74.89%. The firm’s revenue for the quarter was down .2% on a year-over-year basis. During the same period in the previous year, the company earned $1.76 earnings per share. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. On average, research analysts expect that Zoetis Inc. will post 6.2 EPS for the current fiscal year.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.